R&D channel feed – Endpoints News

R&D channel feed

FDA motions Alnylam's lumasiran into a PhIII short track, setting up a shot at an OK in '20

8 years ago

Merck study may signal doom for a broad group of pivotal Alzheimer’s studies

8 years ago

Merck’s snapshot of positive data for frontline lung cancer niche triggers a new scramble for quick Keytruda OK

8 years ago

FDA’s back-to-back punches against biosims from Celltrion, Novartis leave Roche’s big Rituxan franchise untouched

8 years ago

Pharma's broken business model — Part 2: Scraping the barrel in drug discovery

8 years ago

High cholesterol contender Esperion slips on safety concerns, stock sinks 30%

8 years ago

Kymriah wins second FDA OK, boosting hope for Novartis' low CAR-T sales

8 years ago

Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics

8 years ago

Under pressure, Peter Hecht splits Ironwood into two biotechs, spinning out an R&D operation

8 years ago

Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology

8 years ago

IDO rout: Pivotal trials with Bristol-Myers, Merck and AstraZeneca dumped in wake of Incyte's PhIII implosion

8 years ago

Karyopharm stock soars on selinexor's positive PhIIb update, plans for an NDA

8 years ago

Eyeing Eylea's $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

8 years ago

Allergan's $639M Vitae buyout is a bust. R&D writes off their psoriasis program as a complete loss

8 years ago

Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant

8 years ago

Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai

8 years ago

Alexion preps an FDA pitch on Soliris successor while signaling more deals ahead for rare disease drugs

8 years ago

GSK tips its hat on new deals, reviews incentives as Hal Barron cooks up a turnaround plan for its lackluster R&D group

8 years ago

Celgene's disclosures about ozanimod this week spur analysts' fears of a lengthy delay for a key drug

8 years ago

Roche flags first case of anti-drug antibodies that forced a patient to drop would-be blockbuster Hemlibra

8 years ago

After mega-round investment, ADC Therapeutics cans PhI trial in HER2

8 years ago

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

8 years ago

Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff

8 years ago

AstraZeneca’s Imfinzi/tremelimumab combo fizzles again on lung cancer

8 years ago

First page Previous page 274 275 276277278 279 280 Next page Last page